Poster Sessions

Poster Session C: Cancers of the Colon, Rectum, and Anus
Saturday, January 19, 2019 7:00 AM- 7:55 AM and 12:15 PM- 1:45 PM

Trials in Progress Poster Session C: Cancers of the Colon, Rectum, and Anus
Saturday, January 19, 2019 7:00 AM- 7:55 AM and 12:15 PM- 1:45 PM

Posters by Topic
Prevention, Diagnosis, and Screening: Poster Boards C1, C6, C9-E13
Multidisciplinary Treatment: Poster Boards C2-C5, C7, J14-P20
Translational Research: Poster Boards C8, E14-J13
Trials in Progress: Poster Boards Q1-Q16

BOARD C1
Abstract 480: A randomized, double-blinded, placebo-controlled multicenter phase II trial of adjuvant immunotherapy with tecemotide (L-BLP25) after R0/R1 hepatic colorectal cancer metastasectomy (LICC): Final results.
First Author: Carl Schimanski, MD, PhD


BOARD C2
Abstract 481: CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
First Author: Eric Chen, MD, PhD


BOARD C3
Abstract 482: Adjuvant HIPEC in patients with colon cancer at high risk of peritoneal metastases: Primary outcome of the COLOPEC multicenter randomized trial.
First Author: Charlotte Klaver, MD, BA


BOARD C4
Abstract 483: Does a longer waiting period after neoadjuvant radiochemotherapy improve the oncological prognosis of rectal cancer? Three-year follow-up results of the GRECCAR-6 randomized multicenter trial.
First Author: Jeremie Lefevre, MD, PhD


BOARD C5
Abstract 484: A randomized phase III trial of S-1/oxaliplatin (SOX) versus UFT/leucovorin as adjuvant chemotherapy for high-risk stage III colon cancer: The ACTS-CC 02 trial.
First Author: Takao Takahashi, MD, PhD


BOARD C6
Abstract 485: Circulating tumor cell count from a blood sample for colorectal cancer (CRC) prevention: A 627-patient prospective study.
First Author: Wen-Sy Tsai


BOARD C7
Abstract 486: Total neoadjuvant therapy with short course radiation compared to concurrent chemoradiation in rectal cancer.
First Author: William Chapman, MD, MPHS


BOARD C8
Abstract 487: Immunoscore clinical utility to identify good prognostic colon cancer stage II patients with high-risk clinico-pathological features for whom adjuvant treatment may be avoided.
First Author: Jerome Galon, PhD


BOARD C9
Abstract 488: Metastatic patterns and prognostic significance of signet ring cell carcinoma of the colon: Retrospective analysis of SEER database.
First Author: John Khoury, MD


BOARD C10
Abstract 489: Difference of colorectal cancer microbial community by metagenomics and culture-based methods.
First Author: Dong Ho Lee


BOARD C11
Abstract 490: Recent trends in age at diagnosis of colon cancer in the United States, 2004-2015, a National Cancer Database study.
First Author: Boone Goodgame, MD


BOARD C12
Abstract 491: Impact of cardiac comorbidity on use and outcomes of adjuvant chemotherapy (ADJ) for colorectal cancer (CRC): A real-world population-based study.
First Author: Shiru Liu, MD


BOARD C13
Abstract 492: Epidemiological trends of HPV-related anal cancers amongst males globally: A systematic literature review.
First Author: Anuj Walia


BOARD C14
Abstract 493: Use of MLH1 methylation analysis versus BRAF V600E mutation testing to select patients for Lynch syndrome genetic testing in a Chinese population: A large consecutive cohort study.
First Author: Wenmiao Wang, PhD


BOARD C15
Abstract 494: Relation between the size of nonmetastatic and metastatic lymph nodes and outcomes in patients with stage III colon cancer.
First Author: Kazutake Okada, PhD


BOARD C16
Abstract 495: Utility of restaging patients with stage II/III rectal cancer following neoadjuvant chemo/XRT: A systematic review.
First Author: Leah Hendrick, MD


BOARD C17
Abstract 496: Population pharmacokinetics (popPK) of Sym004 to evaluate the effect of intrinsic and extrinsic factors on exposure in metastatic colorectal cancer (mCRC).
First Author: Lene Alifrangis, PhD


BOARD C18
Abstract 497: Sidedness in metastatic colorectal carcinoma: Which are the factors which influence the prognosis?
First Author: Maria Kogay


BOARD D1
Abstract 498: Molecular comparison of primary colorectal cancer (pCRC) with peritoneal metastases (PM).
First Author: Matthew Stein, MD


BOARD D2
Abstract 499: Immunological nomograms predicting prognosis and guiding adjuvant chemotherapy in stage II colorectal cancer.
First Author: Junjie Peng, MD


BOARD D3
Abstract 500: Outcomes of younger patients diagnosed with locally advanced rectal cancer.
First Author: Rosemary Habib, BSc, MBBS, MPharm


BOARD D4
Abstract 501: Safety of compression therapy using newly developed gloves for oxaliplatin induced neuropathy prevention.
First Author: Yukinori Koyama, MD Ph D


BOARD D5
Abstract 502: Survival outcomes of left-sided versus right-sided colon cancer.
First Author: Jasmine Gowarty


BOARD D6
Abstract 503: Streamlining universal screening for lynch syndrome (LS): Towards improved yield of genetic counseling (GC).
First Author: Stefania Sciallero


BOARD D7
Abstract 504: MSI-H testing via hybrid capture based NGS sequencing of liquid biopsy samples.
First Author: Kyle Gowen, B.S.


BOARD D8
Abstract 505: Gene-specific features (MLH1, MSH2, MSH6, PMS2) of mismatch repair (MMR) protein expression and somatic mutations (muts), microsatellite instability (MSI) and tumor mutational burden (TMB) in MSI-H and MMR-mutated tumor genomic profiles (TGPs).
First Author: Michael Hall, MD, MS


BOARD D9
Abstract 506: Novel radiomics signature predicts lymph node metastasis in T1 colorectal carcinoma.
First Author: Yanlei Ma


BOARD D10
Abstract 507: Colorectal cancer (CRC) among very elderly ( > 80 yo) patients (pts): A Brazilian single institution cohort.
First Author: Marcela Crosara Alves Texeira, MD


BOARD D11
Abstract 508: Review of updated colorectal cancer disease management data in the Colombian National Administrative Cancer Registry.
First Author: Robert Hsu, MD, MS


BOARD D12
Abstract 509: Retrospective multicenter study for assessment of association between imaging change and outcome after treatment of regorafenib: KSCC1603.
First Author: Taito Esaki, MD, PhD


BOARD D13
Abstract 510: Early detection of lower GI tract tumors by dedicated assessment of the colon on routine computed tomography (CT) imaging: An observational study.
First Author: John Chang, M.D., Ph.D.


BOARD D14
Abstract 511: The strategy of zero-mortality due to postoperative VTE in patients with colorectal cancer.
First Author: Shoko Iwahashi, MS


BOARD D15
Abstract 512: DNA damage response pathway mutations contribute to a high proportion of hereditary colorectal cancer in patients from the Republic of Macedonia.
First Author: Marija Staninova, MrPharm


BOARD D16
Abstract 513: Patient and disease characteristics of colorectal cancer in a cohort of young patients.
First Author: Wissam Hanayneh, MD


BOARD D17
Abstract 514: Are quantitative measures of visceral adiposity obtained after neoadjuvant chemoradiation associated with postoperative morbidity in patients with locally advanced rectal cancer?
First Author: Leah Hendrick, MD


BOARD D18
Abstract 515: Microsatellite instability detection from plasma of colorectal cancer patients.
First Author: Jing Sun, MD, PhD


BOARD D19
Abstract 516: Prospective clinical study using expressed sequencing variants on stool-derived eukaryotic RNA transcripts (seRNA) for colorectal cancer screening.
First Author: Erica Barnell


BOARD D20
Abstract 517: Financial distress amongst older adults with gastrointestinal (GI) malignancies.
First Author: William Varnado, MD


BOARD E1
Abstract 518: Association between primary tumor site, perioperative CEA ratio, and overall survival in patients with colorectal cancer.
First Author: Thomas Odeny, MD, MPH, PhD


BOARD E2
Abstract 519: Clinical and functional analysis of SOX9 in colorectal cancer.
First Author: Erik Lizarraga, MS


BOARD E4
Abstract 521: Validation of the NCI Colorectal Cancer Risk Assessment Tool for baseline advanced neoplasia in a veterans cohort.
First Author: Laura Musselwhite, MD


BOARD E5
Abstract 522: Characteristics and survival among early onset and standard onset colorectal cancer by race.
First Author: Ana Acuna Villaorduna, MD


BOARD E6
Abstract 523: Prevalence of KRAS, NRAS, and BRAF gene mutations in metastatic colorectal cancer patients: A systematic literature review and meta-analysis.
First Author: Kimberly Lowe


BOARD E7
Abstract 524: Evaluation of routine image follow-up in nonmetastatic colorectal cancer after curative surgical resection.
First Author: Lara Diniz


BOARD E8
Abstract 525: Circulating tumor DNA testing and research in patients with gastrointestinal malignancies.
First Author: Faisal Shahjehan, MD


BOARD E9
Abstract 526: The incidence of infusion reactions associated with monoclonal antibody drugs targeting the epidermal growth factor receptor in metastatic colorectal cancer patients: A systematic literature review and meta-analysis.
First Author: Kimberly Lowe


BOARD E10
Abstract 527: Incidence of pulmonary metastasis among patients with colorectal adenocarcinoma: Correlation between sidedness and RAS mutations.
First Author: Lara Diniz


BOARD E11
Abstract 528: Genomic and immune infiltration differences between MSI and MSS GI tumors.
First Author: Yulia Newton, PhD


BOARD E12
Abstract 529: Racial disparities and treatment outcomes among patients admitted with a diagnosis of colorectal cancer: Analysis of the 2014 national inpatient sample database.
First Author: Ikponmwosa Enofe, MD, MPH


BOARD E13
Abstract 530: On the road again: Travel patterns and outcomes in rectal cancer.
First Author: Mary Kledzik, MD


BOARD E14
Abstract 531: The role of Parvimonas micra in intestinal tumorigenesis in germ-free and conventional APCmin/+ mice.
First Author: Jun Yu


BOARD E15
Abstract 532: High-serum blood sugar level significantly enhances oxaliplatin resistance in stage III colorectal cancer patients.
First Author: Jaw-Yuan Wang, MD, PhD


BOARD E16
Abstract 533: Mismatch repair/microsatellite instability (MMR/MSI) testing practices among United States physicians treating patients (pts) with advanced/metastatic colorectal cancer (mCRC).
First Author: Jennifer Eriksson, MSc


BOARD E17
Abstract 534: Assessment of systemic and metastatic neutrophilic inflammation in synchronously resected colorectal cancer and liver metastases.
First Author: Colin Steele, MRCS, PhD


BOARD E18
Abstract 535: CEA expression patterns determine response and resistance to the CEA-TCB bispecific immunotherapy antibody in colorectal cancer patient derived organoids.
First Author: Reyes Gonzalez Exposito, MD


BOARD E19
Abstract 536: KRAS mutation status to predict response in first-line capox and bevacizumab therapy for metastatic colorectal cancer.
First Author: You Yone, MBBS, MRCP


BOARD E20
Abstract 537: Expanded RAS and BRAF V600 testing as predictive biomarkers for single agent cetuximab in the randomized phase III CO.17 trial.
First Author: Jonathan Loree, MD, MS


BOARD F1
Abstract 538: Anal adenocarcinoma: Treatment outcomes and trends in a rare disease entity.
First Author: Richard White, DO


BOARD F2
Abstract 539: Outcomes by tumor location in patients with metastatic colorectal cancer (mCRC) treated with regorafenib (REG): Final analysis from the prospective, observational CORRELATE study.
First Author: Michel Ducreux, MD, PhD


BOARD F3
Abstract 540: Pretreatment metabolomic markers associated with therapeutic responses to FOLFOX with bevacizumab in chemotherapy-naive patients with colorectal cancer.
First Author: Yusuke Tanigawara, PhD


BOARD F4
Abstract 541: The parametric estimation procedure to predict long-term efficacy on survival from publication data of clinical trials for metastatic colorectal cancer (mCRC).
First Author: Kyongsun Pak, PhD


BOARD F5
Abstract 542: Excision repair cross-complementing group-1 (ERCC1) gene induction in peripheral blood mononuclear cells as a marker of outcome in patients with colorectal cancer treated with oxaliplatin.
First Author: Devika Rao, MD


BOARD F6
Abstract 543: CEA response at four weeks as an early predictor for outcomes in patients (pts) with metastatic colorectal cancer (mCRC) treated with first-line cetuximab-based chemotherapy: A STEP-analysis in the JACCRO CC-05/06 trials.
First Author: Yu Sunakawa, MD, PhD


BOARD F7
Abstract 544: The correlation between DPYD*9A (c.85T > C) genotype and dihydropyrimidine dehydrogenase deficiency phenotype in patients with gastrointestinal malignancies treated with fluoropyrimidines: Updated analysis.
First Author: Anu Singh Maharjan, PhD


BOARD F8
Abstract 545: Germline pharmacogenomics of thymidylate synthase gene in patients with gastrointestinal malignancies treated with fluoropyrimidines-based chemotherapy regimens.
First Author: Saad Awan


BOARD F9
Abstract 546: Occurrence of irreversible sinusoidal obstruction syndrome during adjuvant chemotherapy for colorectal cancer using oxaliplatin: A multi-center study.
First Author: Takeshi Yamada, MD


BOARD F10
Abstract 547: RAS amplified colorectal cancers are enriched in RAS-WT, BRAF-WT, MSS tumors and may predict for anti-EGFR resistance.
First Author: Marwan Fakih, MD


BOARD F11
Abstract 548: Prospective analysis of microRNA 31-3p (miR31-3p) as a predictive biomarker of response to anti-epidermal growth factor receptor (anti-EGFR) monoclonal antibodies (mABs) in patients with metastatic colorectal cancer (mCRC).
First Author: Gayathri Anandappa, MBBS MRCP(UK)


BOARD F12
Abstract 549: Gender and survival benefit from initial irinotecan in metastatic colorectal cancer: Analysis of the XELAVIRI (AIOKRK0110) study.
First Author: Dominik Modest, MD


BOARD F13
Abstract 550: Role of enterocyte-specific gene polymorphisms in adjuvant treatment for stage III colorectal cancer.
First Author: Mitsukuni Suenaga, MD, PhD


BOARD F14
Abstract 551: Anal melanoma: A comparative comprehensive genomic profiling study.
First Author: Jeffrey Ross, MD


BOARD F15
Abstract 552: Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation: Interim results.
First Author: Mikaela Esquivel


BOARD F16
Abstract 553: Classification of BRAF mutated colorectal cancer based on microsatellite stability.
First Author: Michitaka Nakano, MD


BOARD F17
Abstract 554: Prognostic value of genomic alterations (GA) on overall survival in appendiceal adenocarcinoma (AA).
First Author: Alexandre Jacome, MD, PhD


BOARD F18
Abstract 555: The prognostic role of PD-L1 expression according to MSI status in stage III colon cancer after curative resection.
First Author: Sang-Hee Cho, MD, PhD


BOARD F19
Abstract 556: PD-1/PD-L1 immune check points blockade to attenuate growth of metastatic colon cancer in the CBP/β-catenin inhibited liver.
First Author: Kiminori Kimura, MD, PhD


BOARD F20
Abstract 557: Nrf2 metagene as a prognostic biomarker across all stages of colorectal cancer (CRC).
First Author: Sean O'Cathail, MB BCh BAO B.Med.Sci MSc


BOARD G1
Abstract 558: Genetic variations within the CD40L immune stimulating gene predict outcome for mCRC patients treated with first-line FOLFIRI/bevacizumab: Data from FIRE-3 and TRIBE.
First Author: Martin D. Berger, MD


BOARD G2
Abstract 559: Somatic POLE proofreading domain mutations by next generation sequencing to predict outcomes in stage II colorectal cancer.
First Author: Shaobo Mo


BOARD G3
Abstract 560: Impact of genomic alterations (GAs) on outcomes and their distribution by age groups in metastatic colorectal cancer (mCRC) patients (pts).
First Author: Ibrahim Sahin, MD


BOARD G4
Abstract 561: Effects of CDX2 on proliferation and glucose metabolism reprogram by targeting PGAM1 in colorectal cancer.
First Author: Qingguo Li, MD, PhD


BOARD G5
Abstract 562: Using circulating tumor DNA (ctDNA) to predict surgical outcome and postoperative recurrence following neoadjuvant chemoradiation (CRT) for borderline resectable/locally advanced rectal cancer (LARC).
First Author: Susan McDuff, MD, PhD


BOARD G6
Abstract 563: A phase II study of GVAX colon vaccine with cyclophosphamide and pembrolizumab in patients with mismatch repair–proficient (MMR-p) advanced colorectal cancer.
First Author: Mark Yarchoan, MD


BOARD G7
Abstract 564: Genetic variants in the lipopolysaccharide (LPS) receptor complex and TLR4 expression levels to predict efficacy of cetuximab (cet) in patients (pts) with metastatic colorectal cancer (mCRC): Data from the FIRE-3 phase III trial.
First Author: Francesca Battaglin, MD


BOARD G8
Abstract 565: Analysis of UGT1A’s polymorphisms and RAS: RAF mutations based on phase II study of biweekly XELIRI plus bevacizumab as a second-line therapy in patients with metastatic colorectal cancer.
First Author: Hiroaki Tanioka, MD, PhD


BOARD G9
Abstract 566: Polymorphisms in the telomerase complex to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from TRIBE and FIRE-3 phase III trials.
First Author: Francesca Battaglin, MD


BOARD G10
Abstract 567: MACC1 expression as a candidate prognostic biomarker in colorectal cancer patients receiving adjuvant oxaliplatin-based therapy.
First Author: Lynn Symonds, MD


BOARD G11
Abstract 568: Evaluating and manipulating the immune landscape in hepatic verses peritoneal metastases arising from colorectal primary tumors.
First Author: Robert Ramsay, PhD


BOARD G12
Abstract 569: Patient-derived colorectal cancer spheroids for single cell characterization of intratumor heterogenity in response to EGFR inhibition.
First Author: Jeremy Kratz, MD


BOARD G13
Abstract 570: Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer.
First Author: Marina Baretti, MD


BOARD G14
Abstract 571: Survival after secondary liver resection in metastatic colorectal cancer: A comparative analysis of the LICC trial with historical controls (CELIM, FIRE-3).
First Author: Markus Hermann Moehler, MD, PhD


BOARD G15
Abstract 572: CD276-positive circulating endothelial cells in advanced colorectal cancer.
First Author: Elske Gootjes


BOARD G16
Abstract 573: Integrated profiling the patterns of pathologic response to neoadjuvant chemoradiation and the genomic-based radiation sensitivity in rectal cancer.
First Author: Zhigang Yuan, MD, PhD


BOARD G17
Abstract 574: CB-839, panitumumab, and irinotecan in RAS wildtype (WT) metastatic colorectal cancer (mCRC): Phase I results.
First Author: Kristen Ciombor, MD


BOARD G18
Abstract 575: Oncogenic alterations detected by droplet digital PCR in patients with metastatic colorectal cancer resistant to cetuximab.
First Author: Rujiao Liu


BOARD G19
Abstract 576: KRAS mutation is associated with upregulation of integrin beta-4 expression leading to tumor invasion in colorectal cancer.
First Author: Seo-Hyun Choi, Ph.D.


BOARD G20
Abstract 577: Significance of monitoring plasma vascular endothelial growth factor signals during treatment of colorectal cancer patients.
First Author: Nao Kakizawa


BOARD H1
Abstract 578: Identification of site-specific genome alterations in metastatic colorectal cancer: Sub-study 003 of the SCRUM-Japan GI-SCREEN.
First Author: Takuro Mizukami, MD, PhD


BOARD H2
Abstract 579: Comprehensive profiling of immune landscape in gastrointestinal (GI) and head and neck (HN) cancers via computational deconvolution.
First Author: Christopher Szeto, PhD, BS, BA


BOARD H3
Abstract 580: KRAS mutation as a predictor for cause-specific survival in early- versus late-onset colorectal cancer: A United States population-based study.
First Author: Albert Lin, MD, MPH


BOARD H4
Abstract 581: The relationship between tumor budding, tumor microenvironment, and survival in patients with primary operable colorectal cancer.
First Author: Hester Van Wyk, PhD


BOARD H5
Abstract 582: Comparison of phosphoproteomic profiles in left- and right-sided colorectal cancers.
First Author: Tineke Buffart, MD, PhD


BOARD H6
Abstract 583: Predicting the pathologic complete regression with hematologic markers during neoadjuvant chemoradiotherapy in the locally advanced rectal cancer.
First Author: Jae-Sung Kim


BOARD H7
Abstract 584: The impact of sidedness of colorectal cancer in tumor immunity.
First Author: Masaaki Nishi


BOARD H8
Abstract 585: Liquid biopsy for optimizing the rechallenge of cetuximab in metastatic colorectal cancer: Additional study of E-Rechallenge Trial.
First Author: Yoshihito Ohhara, MD


BOARD H10
Abstract 587: Blood-based biomarkers in metastatic colorectal cancer patients treated with FOLFIRI plus regorafenib or placebo: Results from LCCC1029.
First Author: Yingmiao Liu, PhD


BOARD H11
Abstract 588: On-treatment changes of plasma protein biomarkers in CALGB/SWOG 80405 (Alliance).
First Author: Ace Hatch, PhD


BOARD H12
Abstract 589: Characterisation of chemoradiation-induced changes in immune cells and targets for personalized therapy in locally advanced rectal cancer (LARC).
First Author: Elisa Fontana, MD


BOARD H13
Abstract 590: Optimizing treatment with anti-epidermal growth factors receptor (EGFR) drugs for patients with metastatic colorectal cancer (mCRC): Novel mechanisms of resistance beyond RAS.
First Author: Claudia Cardone, MD


BOARD H14
Abstract 591: Epigenetic priming prior to pembrolizumab in mismatch repair-proficient advanced colorectal cancer.
First Author: Adrian Murphy, MBBS, PhD


BOARD H15
Abstract 592: Trifluridine/tipiracil (FTD/TPI) and regorafenib (REG) in patients with metastatic colorectal cancer (mCRC): A single institution retrospective study.
First Author: Anuj Patel, MD


BOARD H16
Abstract 593: Biomarkers of immunotherapy response in rectal adenocarcinoma treated with neoadjuvant chemoradiotherapy.
First Author: Gurveen Kaur, MBBS


BOARD H17
Abstract 594: Th17 cell pathway-related genetic variants in metastatic colorectal cancer: A meta-analysis using TRIBE, MAVERICC, and FIRE-3.
First Author: Ryuma Tokunaga, MD, PhD


BOARD H18
Abstract 595: Guanylate cyclase c (GUCY2C) as a preventative and therapeutic target in colorectal cancers (CRCs) arising through divergent genomic pathways.
First Author: Babar Bashir, MBBS


BOARD H19
Abstract 596: Activity of EGFR inhibition in atypical (non-V600E) BRAF-mutated metastatic colorectal cancer.
First Author: Benny Johnson, DO


BOARD H20
Abstract 597: Association of consensus molecular subtypes (CMS) with time to progression (TTP), progression free survival (PFS), and overall survival (OS) with second-line FOLFIRI ± regorafenib in metastatic colorectal cancer (mCRC).
First Author: Michael Lee, MD


BOARD J1
Abstract 598: CMS-PDX: A 20-gene genomic panel to predict consensus molecular subtypes in patient-derived xenografts (PDX) of colorectal cancer.
First Author: Steven Buechler, PhD


BOARD J2
Abstract 599: ColotypeR gene signature predicts response to cetuximab in colorectal cancer metastases.
First Author: Steven Buechler, PhD


BOARD J3
Abstract 600: Quantifying the evolution of tumor architecture using serial circulating tumor DNA.
First Author: Jason Henry, MD


BOARD J4
Abstract 601: Comprehensive -omic analysis of 152 CRC patients allows greater subclassification than CMS or sidedness alone.
First Author: Christopher Szeto, PhD, BS, BA


BOARD J5
Abstract 602: Detection of methylated BCAT1 and IKZF1 in stage II/III rectal cancer receiving chemoradiation.
First Author: Chin-Tung Chen, MS


BOARD J6
Abstract 603: Lymphotoxin alpha functional germline genetic variant: A future prognostic factor in colorectal cancer?
First Author: Mariana Rocha


BOARD J7
Abstract 604: Comprehensive landscape of gene amplifications (amps) in tissue and circulating tumor DNA (ctDNA) in metastatic colorectal cancer (mCRC).
First Author: Kanwal Raghav, MD, MBBS


BOARD J8
Abstract 605: Alternative chemoradiotherapy to treat locally advanced (LA) anal carcinoma (AC) in patients (pts) with mutations in thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) genes: A case series.
First Author: Wasif Saif, MD, MBBS


BOARD J9
Abstract 606: Characteristics of colorectal cancer (CRC) patients with BRCA1 and BRCA2 mutations.
First Author: Madiha Naseem, MD


BOARD J10
Abstract 607: Racial disparity in gastrointestinal cancer: Insight from national cancer database.
First Author: Maharaj Singh, PhD


BOARD J11
Abstract 608: Risk score and prognosis modeling based on mRNA expressivity in the tumor microenvironment of GI cancers.
First Author: Sunyoung Lee, MD, PhD


BOARD J12
Abstract 609: A KRAS mutation is associated with an immunosuppressive tumor microenvironment in mismatch-repair proficient colorectal cancer.
First Author: Michael Marco, MD


BOARD J13
Abstract 610: CMS subtypes characterized by high TMB shows immunosuppressive microenvironment that implies resistance to immunotherapy.
First Author: Christopher Szeto, PhD, BS, BA


BOARD J14
Abstract 611: The effect of adjuvant chemotherapy for stage III colon cancer in elderly patients.
First Author: Naomi Hayashi


BOARD J15
Abstract 612: The impact of socioeconomic factors on outcomes of patients with locally advanced rectal cancer (LARC).
First Author: Joanna Gotfrit, MD


BOARD J16
Abstract 613: A randomized phase II study comparing oral S-1 plus 24-hour infusion of irinotecan (Iri) and bevacizumab (Bev) with FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer (MCRC).
First Author: Sotaro Sadahiro, MD, PhD


BOARD J17
Abstract 614: The combination of TAS-102 and bevacizumab as the third-line chemotherapy for metastatic colorectal cancer (TAS-CC3 Study).
First Author: Chihiro Kosugi, MD


BOARD J18
Abstract 615: The efficacy of neoadjuvant treatment in locally advanced rectal cancer with dMMR.
First Author: Yanhong Deng, MD, PhD


BOARD K1
Abstract 616: Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: A National Cancer Database (NCDB) analysis.
First Author: Shaakir Hasan, DO


BOARD K2
Abstract 617: Distribution of neuroendocrine marker-positive cells in colorectal cancer tissue and adjacent mucosa.
First Author: Takashi Ogimi, MD


BOARD K3
Abstract 618: Timing of first surveillance colonoscopy in stage I colon cancer patients and the association with colon cancer-specific survival.
First Author: Robert Hines, PhD


BOARD K4
Abstract 619: A systematic review and network meta-analysis of regorafenib and TAS-102 in refractory metastatic colorectal cancer.
First Author: Mohamad Sonbol, MD


BOARD K5
Abstract 620: What is the role of the anti-angiogenic therapy in BRAF (V600E) mutant metastatic colorectal cancer patients in a real-world setting?
First Author: Nieves Martinez Lago, MD, PhD


BOARD K6
Abstract 621: Trends in radiation dose and technique for anal canal squamous cell carcinoma.
First Author: Stephen Abel, DO


BOARD K7
Abstract 622: The prognostic value of systemic inflammatory factors in BRAF (V600E) mutant metastatic colorectal cancer (mCRC).
First Author: Nieves Martinez Lago, MD, PhD


BOARD K8
Abstract 623: Left- versus right-side metastatic colorectal cancer: Teasing out clinicopathologic drivers of disparity in survival.
First Author: Shehara Mendis, MBBS, FRACP


BOARD K9
Abstract 624: Phase I/II study of panitumumab (PANI) combined with trifluridine/tipiracil (FTD/TPI) in patients (pts) with previously treated RAS wild-type (wt) metastatic colorectal cancer (mCRC): Final results of APOLLON study.
First Author: Yoshito Komatsu, MD, PhD


BOARD K10
Abstract 625: Squamous cell carcinoma of the rectum: Practice trends and patient survival.
First Author: Sunil Dutta, MD


BOARD K11
Abstract 626: Withholding anti-EGFR, the impact on outcome in RAS wild-type metastatic colorectal tumors (WAIT or ACT trial).
First Author: Lola-Jade Palmieri


BOARD K12
Abstract 627: Obesity and its impact on outcomes in stage III colon cancer (CC) patients receiving adjuvant chemotherapy (AC).
First Author: Qirui Ding


BOARD K13
Abstract 628: Benefit of adjuvant chemotherapy in patients with high-risk UICC II colon cancer T4N0M0: A ten-year population-based analysis of 3544 cases.
First Author: Andreas Teufel


BOARD K14
Abstract 629: Impact of multidisciplinary management in the diagnosis and treatment of neuroendocrine tumors (NET).
First Author: Gurprataap Sandhu, MBBS


BOARD K15
Abstract 630: A phase I study of TAS-102 in combination with oxaliplatin (TAS-OX) for refractory metastatic colorectal cancer (mCRC).
First Author: Michael Cecchini, MD


BOARD K16
Abstract 631: Early tumor shrinkage and depth of response as predictors of favorable treatment outcomes in patients with metastatic colorectal cancer treated with FOLFOX/FOLFIRI plus cetuximab.
First Author: S.P. Somashekhar


BOARD K17
Abstract 632: A retrospective study of a dexamethasone-sparing strategy of preventing acute and delayed emesis caused by CapeOx regimen with aprepitant for colorectal cancer.
First Author: Miho Nakatsuka, BPharm


BOARD K18
Abstract 633: “Should we be generous in peritonectomy?”: First prospective comparative analysis of total versus involved field parietal peritonectomy in CRS-HIPEC for peritoneal surface malignancies from COLO-rectal cancer—ISPSM collaboration study.
First Author: S.P. Somashekhar


BOARD K19
Abstract 634: Evaluation of the re-introducing FOLFOX or XELOX ± bevacizumab in relapsed colorectal cancer patients treated with oxaliplatin as adjuvant chemotherapy (REACT study).
First Author: Shigeyoshi Iwamoto, MD


BOARD K20
Abstract 635: Nivolumab (NIVO) + low-dose ipilimumab (IPI) in previously treated patients (pts) with microsatellite instability-high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC): Long-term follow-up.
First Author: Michael Overman, MD


BOARD L1
Abstract 636: Lung metastasis as predictor for prognosis in metastatic colorectal cancer with mutated KRAS.
First Author: Ben Boursi


BOARD L2
Abstract 637: Randomized study evaluating trifluridine/tipiracil (TAS-102) versus + trifluridine/tipiracil + bevacizumab as last-line therapy in patients with chemorefractory unresectable metastatic colorectal cancer (mCRC).
First Author: Per Pfeiffer, MD, PhD


BOARD L3
Abstract 638: Health-related quality of life in the early-access phase IIIb study of trifluridine/tipiracil in pretreated metastatic colorectal cancer (mCRC): Results from PRECONNECT study.
First Author: Julien Taieb, MD, PhD


BOARD L4
Abstract 639: Validation of cost-effectiveness of trifluridine/tipiracil versus best supportive care and regorafenib for previously treated metastatic colorectal cancer in the UK using phase IIIb PRECONNECT early access clinical trial data in the real world setting.
First Author: Javier Sabater


BOARD L5
Abstract 640: Outcomes following stereotactic body radiotherapy (SBRT) in locally recurrent rectal cancer (LRRC) in a previously irradiated pelvis.
First Author: Thomas Smith, MBBS, MSc


BOARD L6
Abstract 641: Improving clinician confidence and practice behavior on the therapeutic management of microsatellite-instability high (MSI-H) gastrointestinal (GI) cancers.
First Author: Hamsa Jaganathan, PhD


BOARD L7
Abstract 642: Temporal trends and disease characteristics associated with total neoadjuvant therapy (TNT) usage.
First Author: Laila Babar, MD


BOARD L8
Abstract 643: Cost and effectiveness of genetic testing in metastatic colorectal cancer (mCRC) at Montefiore Medical Center (MMC).
First Author: Nadia Ashai, MD


BOARD L10
Abstract 645: Predicting imminent disease progression in advanced colorectal cancer by a machine-learning algorithm.
First Author: Yuri Kogan, MSc


BOARD L11
Abstract 646: A phase I/II study of pexa-vec oncolytic virus in combination with immune checkpoint inhibition in refractory colorectal cancer: Safety report.
First Author: Maria Pia Morelli, MD, PhD


BOARD L12
Abstract 647: Multicenter phase Ib/ II study of biweekly trifluridine/tipiracil with bevacizumab combination for patients with metastatic colorectal cancer refractory to standard therapies (BiTS study).
First Author: Masahito Kotaka, MD, PhD


BOARD L13
Abstract 648: National trends in intensity modulated radiation therapy (IMRT) use for rectal cancer.
First Author: Zachary Horne


BOARD L14
Abstract 649: The association of age with acute toxicities in NRG oncology combined modality lower GI cancer trials.
First Author: Noam VanderWalde, MD, MS


BOARD L15
Abstract 650: Implementing DPYD*2A genotyping in clinical practice, the Quebec experience.
First Author: Catherine Jolivet


BOARD L16
Abstract 651: Potentially avoidable acute care use among patients receiving oxaliplatin.
First Author: Eric Roeland, MD


BOARD L17
Abstract 652: EXPERT study: Randomized phase III trial of radical surgery and postoperative mFOLFOX6 versus perioperative mFOLFOX6 plus cetuximab in patients with KRAS wild-type resectable colorectal liver metastases (CLMs).
First Author: Yoshihiro Mise, MD, PhD


BOARD L18
Abstract 653: Clinical impact of D3 lymph node dissection preserving left colic artery (LCA) compared to D3 without preserving LCA: Exploratory subgroup analysis of data from randomized controlled trial of laparoscopic versus open surgery for colon cancer from Japan Clinical Oncology Group study JCOG0404.
First Author: Tomonori Akagi


BOARD L19
Abstract 654: The impact of psychosocial distress on survival in patients diagnosed with gastrointestinal (GI) malignancies.
First Author: Zamzam Al-Hashami, MD


BOARD L20
Abstract 655: Long-term outcomes of surgical resection of lung metastases from colorectal cancer.
First Author: Ryota Mori


BOARD M1
Abstract 656: Systematic review of three decades of clinical trials in metastatic colorectal cancer: Making lemonade out of lemons?
First Author: Daniel Tannenbaum, MD


BOARD M2
Abstract 657: Clinical implications of microsatellite instability in mucinous colorectal cancer.
First Author: Fergus Keane, MRCP


BOARD M3
Abstract 658: Genomic alterations in appendiceal carcinoma using circulating DNA.
First Author: Walid Shaib, MD


BOARD M4
Abstract 659: Clinicopathological features, efficacy of anti-EGFR therapy, and survival outcomes in patients with BRAF non-V600 mutated metastatic colorectal cancer.
First Author: Daisuke Kotani, MD


BOARD M5
Abstract 660: Identifying the importance of integrating routine pharmacogenomic testing for UGT1A1 and DPYD/tyms genetic variants in patients receiving irinotecan and/or 5-fluorouracil chemotherapy.
First Author: Candice Baldeo, MBBS


BOARD M6
Abstract 661: A prospective study of robotic rectal surgery for carcinoma rectum assessing the functional and oncological outcomes: Hype or hope?
First Author: S.P. Somashekhar


BOARD M7
Abstract 662: Simultaneous resection of colorectal cancer with synchronous liver metastases: A survey-based analysis.
First Author: Christopher Griffiths, M.D.


BOARD M8
Abstract 663: Ambulatory 5FU infusion pumps: Patient perceptions and quality of life.
First Author: Munaf Al-Kadhimi, MD


BOARD M9
Abstract 664: Safety of bevacizumab in cancer patients with inflammatory bowel disease.
First Author: Ruth Gabriela Herrera Gomez, MD


BOARD M10
Abstract 665: Simultaneous versus staged resection for synchronous colorectal cancer liver metastases: A population-based cohort study.
First Author: Jessica Bogach


BOARD M11
Abstract 666: Nintedanib versus placebo in patients receiving mFOLFOX6 for metastatic, chemorefractory colorectal cancer: TRICC-C trial—Final results from the randomized phase II trial of the AIO.
First Author: Thomas Ettrich, MD


BOARD M12
Abstract 667: Integrating geriatric assessment into routine gastrointestinal (GI) consultation: The Cancer and Aging Resilience Evaluation (CARE).
First Author: Grant Williams, MD


BOARD M13
Abstract 668: Real-world experience of trifluridine/tipiracil in patients with metastatic colorectal cancer: A multicenter United Kingdom study.
First Author: Chara Stavraka, MBBS, MRCP, PhD


BOARD M14
Abstract 669: FOLFOX rechallenge versus regorafenib in patients with metastatic colorectal cancer refractory to standard chemotherapy: A retrospective analysis.
First Author: Maria Alessandra Calegari, MD


BOARD M15
Abstract 670: Safety and clinical activity of durvalumab monotherapy in patients with microsatellite instability–high (MSI-H) tumors.
First Author: Neil Segal, MD, PhD


BOARD M16
Abstract 671: The impact of multidisciplinary team (MDT) management on outcome of hepatic resection in liver-limited colorectal metastases.
First Author: Salvatore Corallo, MD


BOARD M17
Abstract 672: Predictors of survival in rectal squamous cell carcinoma: An analysis from the National Cancer Database (NCDB).
First Author: Sri Tella


BOARD M18
Abstract 673: Surgery versus surgery with adjuvant radiotherapy for T4 colon cancer.
First Author: Nikhil Sebastian


BOARD M19
Abstract 674: Phase III randomized, placebo-controlled, double-blind study of monosialotetrahexosylganglioside in prevention of oxaliplatin-induced neurotoxicity in stage II/III colorectal cancer patients.
First Author: Yu-hong Li


BOARD M20
Abstract 675: Patterns of adjuvant therapy use and survival outcomes in patients with rectal cancer not receiving neoadjuvant therapy in an Australian cohort.
First Author: Kate Wilkinson


BOARD N1
Abstract 676: QoL from TASCO1: Health-related quality of life of trifluridine/tipiracil-bevacizumab and capecitabine-bevacizumab as first-line treatments in metastatic colorectal cancer patients not eligible for intensive chemotherapy—Results from the TASCO1 phase II study.
First Author: Vladimir Moiseyenko, MD, PhD


BOARD N2
Abstract 677: Exploratory analysis of the effect of FTD/TPI in patients treated in RECOURSE by prognostic factors.
First Author: Josep Tabernero, MD, PhD


BOARD N3
Abstract 678: Rectal cancer treatment and outcomes in elderly patients treated with curative intent.
First Author: Sharlyn Kang, MBBS


BOARD N4
Abstract 679: Sequencing of different targeted therapies in management of KRAS wild-type metastatic colorectal cancer: A meta-analysis.
First Author: Jin Li, MD


BOARD N5
Abstract 680: A phase Ib study of pembrolizumab (Pem) in combination with stereotactic body radiotherapy (SBRT) for resectable liver metastatic colorectal cancer (CRC).
First Author: Anita Turk, MD, BA


BOARD N6
Abstract 681: Watch and wait approach following neoadjuvant chemoradiotherapy for rectal cancer patients: A single-centre experience.
First Author: Ji Zhu, MD


BOARD N7
Abstract 682: Retrospective analysis of clinical characteristics of mCRC patients receiving three or more lines of chemotherapy.
First Author: Pilar Garcia Alfonso, MD


BOARD N8
Abstract 683: Trecc: Re-challenge therapy with anti-EGFR in metastatic colorectal adenocarcinoma (mCRC).
First Author: Amanda Karani


BOARD N9
Abstract 684: Feasibility of using a fitness tracker to assess activity level and toxicity in colorectal cancer patients.
First Author: William Ward, MD, MS


BOARD N10
Abstract 685: Evaluating the prognostic significance of lymphovascular invasion in stage II and III colon cancer.
First Author: Dorotea Mutabdzic, MD, MEd


BOARD N11
Abstract 686: Dose-finding and single-arm confirmatory study of definitive chemoradiotherapy (dCRT) with S-1/mitomycin-C (MMC) in patients (pts) with clinical (c) stage II/III squamous cell carcinoma of the anal canal (SCCA): JCOG0903.
First Author: Atsuo Takashima, MD, PhD


BOARD N12
Abstract 687: Impact of sarcopenia on outcomes in patients with rectal carcinoma treated with trimodality therapy.
First Author: Maria Sandoval, MS


BOARD N13
Abstract 688: Updated results of the BEACON CRC safety lead-in: Encorafenib (ENCO) + binimetinib (BINI) + cetuximab (CETUX) for BRAFV600E-mutant metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz, MD, PhD


BOARD N14
Abstract 689: Determining optimal follow up for patients with anal cancer following chemoradiation.
First Author: Marissa Frazer, MS


BOARD N15
Abstract 690: Predictors of treatment response in colorectal high-grade neuroendocrine carcinomas (HGNEC): A single institution experience.
First Author: Virginia Corbett


BOARD N16
Abstract 691: Disease characteristics and treatment outcomes of young colorectal cancer patients.
First Author: Hiral Parekh, MD, MPH


BOARD N17
Abstract 692: Organ preservation in rectal cancer patients treated with total neoadjuvant therapy.
First Author: Rosa Jimenez-Rodriguez, MD, PhD


BOARD N19
Abstract 694: Phase I study of preoperative capecitabine and lenvatinib with external radiation therapy in locally advanced rectal adenocarcinoma.
First Author: Jessica Frakes, MD, MD


BOARD N20
Abstract 695: HIPEC scoring system: A preoperative model including clinical and radiographic parameters to improve patient selection.
First Author: Gabrielle Gauvin, MD


BOARD P1
Abstract 696: A multivariate model to define risk groups among patients with curatively resected stage I and II colon carcinoma: Final report of a retrospective cohort study.
First Author: Luis Onate-Ocana, MD, MSc


BOARD P2
Abstract 697: Wait times for colorectal cancer patients in a universal healthcare system over a decade: Is it sustainable?
First Author: Megan Delisle, MD


BOARD P3
Abstract 698: Stage II and III rectal adenocarcinoma outcomes related to lymphovascular invasion.
First Author: Shalana O'Brien, MD


BOARD P4
Abstract 699: Assessing hematologic ratios as biomarkers for psychosocial distress.
First Author: Abigail Fong, MD, MBA


BOARD P5
Abstract 700: Gastrostomy tube for nutrition and bowel obstruction in patients with advanced malignancy: Less is more.
First Author: Gabrielle Gauvin, MD


BOARD P6
Abstract 701: Outcomes and utilization of adjuvant chemotherapy (AT) for stage II colon cancer (CC-II) in elderly population.
First Author: Afsaneh Barzi, MD, PhD


BOARD P7
Abstract 702: Molecular analysis of advanced colorectal cancer in an ethnically diverse patient population at a single institution.
First Author: Nadia Ashai, MD


BOARD P8
Abstract 703: Pharmacogenomics-guided chemotherapy and supportive care for patients with metastatic colorectal cancer.
First Author: Pashtoon Kasi, MD, MSc


BOARD P9
Abstract 704: Neoadjuvant treatment in a Mexican cohort of patients with locally advanced rectal cancer: Oncologic outcomes and prognostic factors.
First Author: Zuleyma Nieto Garcia, MD


BOARD P10
Abstract 705: The relationship between aortoiliac calcification and long-term outcome in rectal cancer resection.
First Author: Katrina Knight


BOARD P11
Abstract 706: Recurrence pattern and outcomes in T4 colon cancer: A single institution analysis.
First Author: David Macari, MD


BOARD P12
Abstract 707: Comorbidity and systemic inflammation are independent prognostic factors in patients with colorectal cancer: A ScotScan collaborative study.
First Author: James Park, MRCS


BOARD P13
Abstract 708: Effect of time between diagnosis and surgery in colorectal cancer patients on mortality.
First Author: Benjamin Fangman, MD


BOARD P14
Abstract 709: Total neoadjuvant therapy compared with standard therapy in locally advanced rectal cancer: A systematic review and meta-analysis.
First Author: Sashidhar Manthravadi, MD


BOARD P15
Abstract 710: Racial effect of early stage colorectal cancer outcomes in a comprehensive cancer center.
First Author: Benjamin Fangman, MD


BOARD P16
Abstract 711: Impact of the prior chemotherapy with two different fluoropyrimidines on the efficacy of CapeIRI or FOLFIRI in metastatic colorectal cancer: An exploratory analysis of the phase III AXEPT trial.
First Author: Tae Won Kim, MD


BOARD P17
Abstract 712: Synchronous brain metastasis and impact of primary tumor side in colorectal cancers.
First Author: Mahvish Muzaffar, MD


BOARD P18
Abstract 713: Nodal retrieval and short-term outcomes of robotic and laparoscopic colectomies for colon cancer.
First Author: Trang Nguyen


BOARD P19
Abstract 714: Pelvic radiotherapy in combination with radical resection of the primary tumor improves survival in patients with metastatic rectal adenocarcinoma: A national cancer database analysis (NCDB).
First Author: Paul Renz, DO


BOARD P20
Abstract 715: Patterns of care and outcomes of low-lying adenocarcinoma and squamous cell carcinoma of the rectum.
First Author: Paul Adedoyin, MD


BOARD Q1
Abstract TPS716: NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or n plus cetuximab (C) in patients (pts) with "quadruple wild-type (WT)" (KRAS/NRAS/BRAF/PIK3CA WT) metastatic colorectal cancer (mCRC) based on HER2 status - Amplified (amp), non-amplified (non-amp), WT, or mutated (mt).
First Author: Samuel Jacobs, MD


BOARD Q2
Abstract TPS717: SYNERGY-AI: Artificial intelligence based precision oncology clinical trial matching and registry.
First Author: Selin Kurnaz, PhD


BOARD Q3
Abstract TPS718: Open-label phase II/III study of nivolumab plus standard of care versus standard of care for first-line treatment of metastatic colorectal cancer: Checkmate-9X8.
First Author: Josep Tabernero, MD, PhD


BOARD Q4
Abstract TPS719: NuTide:302: A phase Ib study to assess the safety, pharmacokinetics and clinical activity of the ProTide NUC-3373 when combined with standard agents used in colorectal cancer.
First Author: T.R. Jeffry Evans, MD


BOARD Q5
Abstract TPS720: ABT-165 plus FOLFIRI versus bevacizumab plus FOLFIRI in patients with metastatic colorectal cancer (mCRC) previously treated with fluoropyrimidine/oxaliplatin and bevacizumab.
First Author: Zev Wainberg, MD


BOARD Q6
Abstract TPS721: A phase II clinical trial platform for sensitization testing using total neoadjuvant therapy (TNT) in rectal cancer: Nrg-GI002.
First Author: Thomas George, MD, FACP


BOARD Q7
Abstract TPS722: The Global POLAR program: Calmangafodipir used on top of modified FOLFOX6 (5-FU/FA and oxaliplatin) to prevent chemotherapy induced peripheral neuropathy (CIPN).
First Author: Per Pfeiffer, MD, PhD


BOARD Q8
Abstract TPS723: Nintedanib in metastatic appendiceal carcinoma.
First Author: Birendra Kc


BOARD Q9
Abstract TPS724: CO.28: Neoadjuvant Chemotherapy, Excision and Observation (NEO) for early rectal cancer.
First Author: Hagen Kennecke, MD


BOARD Q10
Abstract TPS725: Phase Ib study of talimogene laherparepvec (T-VEC) injection into liver metastases (LMs) in combination with intravenous (IV) atezolizumab in patients (pts) with metastatic triple-negative breast cancer (TNBC) or colorectal cancer (CRC).
First Author: J. Hecht, MD


BOARD Q11
Abstract TPS726: Evaluation of health-related quality of life (HRQoL) in patients with metastatic colorectal cancer (mCRC): A prospective, multicenter, open-label, double-arm trial of trifluridine/tipiracil (FTD/TPI) versus best supportive care (BSC).
First Author: Meinolf Karthaus, MD


BOARD Q12
Abstract TPS727: NSABP FR-2: Phase II study of durvalumab following neoadjuvant chemoRT in stage II-IV rectal cancer.
First Author: Thomas George, MD, FACP


BOARD Q13
Abstract TPS728: COlorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study (NRG- GI004/SWOG-S1610): A randomized phase III study of mFOLFOX6/bevacizumab combination chemotherapy with or without atezolizumab or atezolizumab monotherapy in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) metastatic colorectal cancer (mCRC).
First Author: James Lee, MD, PhD


BOARD Q14
Abstract TPS729: PD-1 antibody combined with COX inhibitor in MSI-h/dMMR or high tmb colorectal cancer: A single arm phase II study.
First Author: Zehua Wu


BOARD Q15
Abstract TPS730: A phase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOX and bevacizumab as first-line (1L) therapy in patients (pts) with metastatic colorectal cancer (mCRC) with or without PTEN loss.
First Author: Sunil Sharma, MD, FACP, MBA


BOARD Q16
Abstract TPS731: Phase II study of avelumab in combination with cetuximab in pre-treated RAS wild-type metastatic colorectal cancer patients: CAVE (cetuximab-avelumab) Colon.
First Author: Teresa Troiani